HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.

Abstract
Neuroblastoma is a common pediatric malignancy that metastasizes to the liver, bone, and other organs. Children with metastatic disease have a less than 50% chance of survival with current treatments. Insulin-like growth factors (IGFs) stimulate neuroblastoma growth, survival, and motility, and are expressed by neuroblastoma cells and the tissues they invade. Thus, therapies that disrupt the effects of IGFs on neuroblastoma tumorigenesis may slow disease progression. We show that NVP-AEW541, a specific inhibitor of the IGF-I receptor (IGF-IR), potently inhibits neuroblastoma growth in vitro. Nordihydroguaiaretic acid (NDGA), a phenolic compound isolated from the creosote bush (Larrea divaricata), has anti-tumor properties against a number of malignancies, has been shown to inhibit the phosphorylation and activation of the IGF-IR in breast cancer cells, and is currently in Phase I trials for prostate cancer. In the present study in neuroblastoma, NDGA inhibits IGF-I-mediated activation of the IGF-IR and disrupts activation of ERK and Akt signaling pathways induced by IGF-I. NDGA inhibits growth of neuroblastoma cells and induces apoptosis at higher doses, causing IGF-I-resistant activation of caspase-3 and a large increase in the fraction of sub-G0 cells. In addition, NDGA inhibits the growth of xenografted human neuroblastoma tumors in nude mice. These results indicate that NDGA may be useful in the treatment of neuroblastoma and may function in part via disruption of IGF-IR signaling.
AuthorsGary E Meyer, Louis Chesler, Dandan Liu, Karissa Gable, Betty A Maddux, David D Goldenberg, Jack F Youngren, Ira D Goldfine, William A Weiss, Katherine K Matthay, Stephen M Rosenthal
JournalJournal of cellular biochemistry (J Cell Biochem) Vol. 102 Issue 6 Pg. 1529-41 (Dec 15 2007) ISSN: 0730-2312 [Print] United States
PMID17486636 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright (c) 2007 Wiley-Liss, Inc.
Chemical References
  • NVP-AEW541
  • Pyrimidines
  • Pyrroles
  • Propidium
  • Insulin-Like Growth Factor I
  • Masoprocol
  • Receptor, IGF Type 1
  • Proto-Oncogene Proteins c-akt
  • Extracellular Signal-Regulated MAP Kinases
  • Caspase 3
Topics
  • Animals
  • Apoptosis (drug effects)
  • Caspase 3 (metabolism)
  • Cell Culture Techniques
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Enzyme Activation (drug effects)
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Humans
  • Insulin-Like Growth Factor I (antagonists & inhibitors)
  • Masoprocol (pharmacology)
  • Mice
  • Mice, Nude
  • Neuroblastoma (drug therapy, pathology)
  • Phosphorylation (drug effects)
  • Propidium (metabolism)
  • Proto-Oncogene Proteins c-akt (antagonists & inhibitors)
  • Pyrimidines (pharmacology)
  • Pyrroles (pharmacology)
  • Receptor, IGF Type 1 (antagonists & inhibitors)
  • Signal Transduction (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: